Understanding Key Issues in the Treatment of Castrate-Resistant Prostate Cancer
Source: Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Module

David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the criteria by which a patient is classified as castrate resistant
  • Describe current treatment approaches for patients with castrate-resistant prostate cancer
  • Explain factors to consider when choosing treatment options for castrate-resistant prostate cancer patients
  • Cite novel research advances and therapeutic treatment options for the treatment of patients with castrate-resistant prostate cancer

Topics covered include:

  • Introduction
  • Definition of CRPC, Androgen-Independent Prostate Cancer, and Hormone-Refractory Prostate Cancer
  • Influence of Metastatic Site on Treatment Course
  • Optimal Androgen-Deprivation Therapy
  • Value of Secondary Hormone Therapy: Who Are the Ideal Candidates?
  • Current Treatment Approaches for CRPC
  • Therapeutic Alternatives Following Docetaxel Failure
  • Factors Influencing Choice of Treatment
  • Nomograms for the Treatment of CRPC
  • Future Strategies and Clinical Trial Data for CRPC
  • Future Treatment Approaches for CRPC: Bone Targeting Strategies
  • Immunotherapy for CRPC
 

Program Directors

  • David I. Quinn
    MD, PhD
    Nicholas J. Vogelzang
    MD

Faculty

  • David I. Quinn
    MD, PhD

Credit Information

  • Release Date:
    February 20, 2009
  • Expiration Date:
    February 19, 2010
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

 

Program Directors

David I. Quinn, MD, PhD
Associate Professor of Medicine
Division of Cancer Medicine and Blood Diseases
The University of Southern California
Medical Director
USC Norris Cancer Hospital and Clinics
Los Angeles, California

David I. Quinn, MD, PhD, discloses that he has received consulting fees and fees for non-CME activities from Sanofi Aventis.

 

Nicholas J. Vogelzang, MD

Research Medical Director 
Associate Chair
, GU Committee
US Oncology Research
Comprehensive Cancer Centers of Nevada
Professor of Medicine
University of Nevada School of Medicine
Las Vegas, Nevada

Nicholas J. Vogelzang, MD, discloses that he has received consulting fees from 4G Vaccines Pty Ltd and contracted research funds from Allos, Genentech, Novartis, Onyx, and Wilex.

 

Faculty

David I. Quinn, MD, PhD


Associate Professor of Medicine
Division of Cancer Medicine and Blood Diseases
The University of Southern California
Medical Director
USC Norris Cancer Hospital and Clinics
Los Angeles, California
David I. Quinn, MD, PhD, discloses that he has received consulting fees and fees for non-CME activities from Sanofi Aventis. 
 

Staff

Deborah Janssen, MS


Senior Managing Editor
Clinical Care Options, LLC

Deborah Janssen, MS, has no significant relationships to disclose.
 

Andrew D. Bowser, ELS


Editorial Director, Hematology/Oncology
Clinical Care Options, LLC

Andrew D. Bowser, has no significant relationships to disclose.
 

Edward King, MA


Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no significant relationships to disclose.
 

Wilma Guerra, ELS


Associate Managing Editor
Clinical Care Options, LLC

Wilma Guerra, ELS, has no significant relationships to disclose.
 

Jim Mortimer, 


Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no significant financial relationships to disclose.
 

Lisa M. Cockrell, PhD


Editorial Contributor

Lisa Cockrell has no significant relationships to disclose.
 

The content of this activity has been reviewed by an independent peer reviewer to ensure that it is balanced, objective, and free from any commercial bias. The peer reviewer has disclosed no financial relationships relevant to the content of this activity.

The following PIM clinical content reviewers, Linda Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kirkwood, RN, BSN and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians and other healthcare professionals who treat patients with prostate cancer.


Goal

The goal of this activity is to enhance the quality of care provided by healthcare professionals treating patients with prostate cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the criteria by which a patient is classified as castrate resistant
  • Describe current treatment approaches for patients with castrate-resistant prostate cancer
  • Explain factors to consider when choosing treatment options for castrate-resistant prostate cancer patients
  • Cite novel research advances and therapeutic treatment options for the treatment of patients with castrate-resistant prostate cancer
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from sanofi-aventis.

 

Program Medium


This program has been made available online, and in print.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 20, 2009, through February 19, 2010:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.